News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Analysis Suggests Pricey Gilead Sciences, Inc. (GILD) Drug Will Bust State Budgets


7/18/2014 7:49:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Will the cost of new hepatitis C treatments bust state budgets?

A new analysis suggests many states may, in fact, be overwhelmed as they attempt to pay for the Solvaldi medication sold by Gilead Sciences (GILD)which costs $84,000 for each patient, and several forthcoming treatments that may be priced at a similar level.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES